CureVac N.V. CVAC 深 滬
已收盤 01-06 16:00:00 美东时间
4.66
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 4.66
- 總市值 104.85万
- 52周最高 5.72
- 市盈率 靜 5.96
- 換手率 0.00%
- 52周最低 2.475
- 委 比 0.00%
- 總股本 0.00亿
- 歷史最高 151.80
- 量 比 0
- 振 幅 0.00%
- 歷史最低 2.215
- 每 手 1
- 風險率 0.34%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BioNTech 2026年第二季度财报：营收下滑，全年指引下调
BioNTech（BNTX）2026年第二季度营收1.056亿欧元，同比下降约59.5%；IFRS净亏损8.208亿欧元，稀释EPS为-3.24欧元，公司同时下调全年营收和调整后研发费用指引。
08-05 06:40
BioNTech Slides As Vaccine Sales Drop, Restructuring Plan Takes Shape
BioNTech shares fall after Q1 revenue miss and wider net loss, despite lower-than-expected loss and long-term cost-saving plans.
05-06 00:18
Inventiva announces CFO appointment
Inventiva (IVA) appointed Axel-Sven Malkomes as chief financial officer. Former CFO Jean Volatier becomes EVP Finance & CSR. Malkomes brings 30+ years of experience, including prior roles at CureVac a...
04-23 04:21
CureVac Completes BioNTech-Driven Reorganization and Moves to Delist from Nasdaq
CureVac ( ($CVAC) ) just unveiled an update. On January 6, 2026, CureVac N.V. c...
01-06 19:29
BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field
BioNTech完成对CureVac的收购，收购比例达86.75%，剩余股份将于2026年1月通过强制收购完成。此次收购将增强BioNTech在mRNA设计、递送配方和生产方面的能力。CureVac将继续运营，BioNTech将进行战略分析以确定未来架构。
2025-12-18 09:45
BioNTech Achieves Minimum Condition in CureVac Exchange Offer
BioNTech announced that the minimum condition for its exchange offer of CureVac shares has been met, with approximately 81.74% of CureVac's outstanding shares tendered. The subsequent offering period has begun and will expire on December 18, 2025. BioNTech will now deliver ADSs or cash to tendering CureVac shareholders, completing the transaction. Non-tendering holders will receive ADSs through the post-offer reorganization, subject to a 15% Dutc...
2025-12-03 14:01
CureVac Shareholders Approve BioNTech Exchange Offer
CureVac ( ($CVAC) ) just unveiled an announcement. On November 25, 2025, CureVa...
2025-11-26 23:27
BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration
BioNTech announced the approval of its exchange offer for all outstanding shares of CureVac at an extraordinary general meeting held on November 25, 2025. Over 99.16% of CureVac shareholders voted in favor of the proposals. The offer is set to expire at 9:00 am Eastern Time on December 3, 2025, with shareholders advised to tender their shares by 6:00 pm Eastern Time on December 2, 2025. The exchange ratio is 0.05363 of a BioNTech ADS per CureVac ...
2025-11-26 12:30
